ZURICH, Sept 5 (Reuters) - Novartis NOVN.S on Tuesday published half year results for Sandoz and confirmed it plans to spin-off its generic medicines division on Oct. 4.
Sandoz achieved net third-party sales of $4.8 billion in the first half of the year, driven by an increase in volume, which was partly offset by negative price affects.
Guidance for 2023 and the mid-term, from 2024 to 2028, was also confirmed.
(Reporting by Noele Illien; Editing by Christian Schmollinger)
((Noele.Illien@thomsonreuters.com; +41 41 528 39 73;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.